Improved biological activity of a mutant endostatin containing a single amino-acid substitution

British Journal of Cancer

Volumn 90, Issue 8, 2004, Pages 1627-1635

  Yokoyama, Y ^a   Ramakrishnan, S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Colon cancer; Endostatin; Ovarian cancer; Point mutation; Tumour angiogenesis

Indexed keywords

ALGINIC ACID; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ASPARAGINYLGLYCYLARGININE; ENDOSTATIN; ENDOTHELIAL CELL GROWTH FACTOR; MICROSOMAL AMINOPEPTIDASE; MUTANT PROTEIN; PEPTIDE FRAGMENT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MICROENCAPSULATION; MOUSE; NONHUMAN; OVARY CANCER; PEPTIDE ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN MOTIF; REAL TIME POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM; ANIMAL; BIOSYNTHESIS; CELL DIVISION; CELL MOTION; COLON TUMOR; DOWN REGULATION; FEMALE; GENETICS; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; OVARY TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION;

AMINO ACID SUBSTITUTION; ANGIOPOIETIN-1; ANIMALS; CELL DIVISION; CELL MOVEMENT; COLONIC NEOPLASMS; DOWN-REGULATION; ENDOSTATINS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; POINT MUTATION; POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2442586625     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601745     Document Type: Article

References (34)

1. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380
2. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance (see comments). Nature 390: 404-407
3. Calvo A, Yokoyama Y, Smith LE, Ali I, Shih SC, Feldman AL, Libutti SK, Ramakrishnan S, Green JE (2002) Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer 101: 224-234
4. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942
5. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, Simons M, Sukhatme VP (1999) Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 59: 189-197
6. Ding YH, Javaherian K, Lo KM, Chopra R, Boehm T, Lanciotti J, Harris BA, Li Y, Shapiro R, Hohenester E, Timpl R, Folkman J, Wiley DC (1998) Zinc-dependent dimers observed in crystals of human endostatin. Proc Natl Acad Sci USA 95: 10443-10448
7. Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstrom A, Timpl R, Welsh M, Claesson-Welsh L (2000) Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95: 3403-34011
8. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N (2000) Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60: 6253-6258
9. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM, Noel A (2002) The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 16: 1802-1804
10. Hanai J, Karumanchi SA, Kale S, Tank J, Hu G, Chan B, Ramchandran R, Jha V, Sukhatme VP, Sokol S (2002) Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol 158: 529-539
11. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R (2000) Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275: 1209-1215
12. Karumanchi SA, Jha V, Ramchandran R, Karihaloo A, Tsiokas L, Chan B, Dhanabal M, Hanai JI, Venkataraman G, Shriver Z, Keiser N, Kalluri R, Zeng H, Mukhopadhyay D, Chen RL, Lander AD, Hagihara K, Yamaguchi Y, Sasisekharan R, Cantley L, Sukhatme VP (2001) Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 7: 811-822
13. Kasai S, Nagasawa H, Shimamura M, Uto Y, Hori H (2002) Design and synthesis of antiangiogenic/heparin-binding arginine dendrimer mimicking the surface of endostatin. Bioorg Med Chem Lett 12: 951-954
14. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, Kwon YG (2000) Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60: 5410-5413
15. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pine-Shepherd SR, Folkman J (2001) Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61: 7669-7674
16. Lin HC, Chang JH, Jain S, Gabison EE, Kure T, Kato T, Fukai N, Azar DT (2001) Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci 42: 2517-2524
17. Maeshima Y, Colorado PC, Kalluri R (2000) Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275: 23745-23750
18. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285
19. Oh SP, Kamagata Y, Muragaki Y, Timmons S, Ooshima A, Olsen BR (1994) Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci USA 91: 4229-4233
20. Olson TA, Mohanraj D, Ramakrishnan S (1996) In vivo neutralization of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth. Int J Oncol 8: 505-511
21. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60: 722-727
22. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D (1996) Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56: 1324-1330
23. Ramchandran R, Dhanabal M, Volk R, Waterman MJ, Segal M, Lu H, Knebelmann B, Sukhatme VP (1999) Antiangiogenic activity of resitin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 255: 735-739
24. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, Pihlajaniemi T, Alitalo K, Vuori K (2001) Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 98: 1024-1029
25. Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L, Lindahl U, Hohenester E, Timpl R (1999) Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J 18: 6240-6248
26. Shichiri M, Hirata Y (2001) Antiangiogenesis signals by endostatin. FASEB J 15: 1044-1053
27. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J (1999) The generation of endostatin is mediated by elastase. Cancer Res 59: 6052-6056
28. Wickstrom SA, Alitalo K, Keiski-Oja J (2002) Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 62: 5580-5589
29. Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW (2000) Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res 59: 368-376
30. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen BR (1999) Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18: 4414-4423
31. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S (2000) Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 60: 2190-2196
32. Yokoyama Y, Ramakrishnan (2002) Substitution of a single amino acid residue in human endostatin potentiates inhibition of ovarian and colon cancer growth. Keystone Symposia.
33. Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, Tanabe KK (1999) Mouse endostatin inhibits the formation of lung and liver metastases (in process citation). Cancer Res 59: 6251-6256
34. Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM, Pollock RE (2000) Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 60: 3655-3661